In January 2016, the
Federal Trade Commission (FTC) settled with
Lumosity which sold "brain training" programs or other products intended to improve cognitive function. FTC settled with LearningRx for $200,000 for similar reasons. The FTC stated LearningRx made unproven assertions in its marketing materials that clinical trials had demonstrated LearningRx helped increase people's IQ and income and mitigated clients' medical issues. In its lawsuit, the FTC said LearningRx had been "deceptively claim[ing] their programs were clinically proven to permanently improve serious health conditions like ADHD (attention deficit hyperactivity disorder), autism, dementia, Alzheimer's disease, strokes, and concussions". LearningRx had made these claims on its website,
Facebook,
Twitter,
advertising mail, as well as in advertisements in newspapers and on radio. In 2016, LearningRx settled with the FTC by agreeing not to make the disputed assertions unless they had "competent and reliable scientific evidence" which was defined as
randomized controlled trials done by competent scientists. For the judgment's monetary component, LearningRx agreed to pay $200,000 of a $4 million settlement. ==Reception==